CureVac N.V. (CVAC) – Company Press Releases
-
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
-
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
-
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
-
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
-
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
-
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
-
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
-
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
-
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
-
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
-
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
-
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
-
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
-
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
-
Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology
-
CureVac Announces Update to the Management Team
-
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
-
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
-
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
-
CureVac Announces Voting Results of General Meeting
-
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
-
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
-
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
-
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
-
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
-
CureVac Announces Voting Results of Extraordinary General Meeting
-
CureVac Announces Voting Results of Extraordinary General Meeting
-
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
-
CureVac Announces Proposed Public Offering of Common Shares
-
CureVac Welcomes Myriam Mendila as New Chief Development Officer
-
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
-
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
-
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
-
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
-
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
-
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
-
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
-
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
-
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
-
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
-
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
-
CureVac Announces Voting Results of General Meeting
-
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
-
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
-
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
-
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
-
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
-
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
-
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
-
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
Back to CVAC Stock Lookup
